LIFE aTyr Pharma, Inc.

3.55
+0.1  (2.9%)
Previous Close 3.45
Open 3.50
Price To book 1.11
Market Cap 84.20M
Shares 23,718,000
Volume 54,581
Short Ratio 2.68
Av. Daily Volume 225,765

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 1H 2017.
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Data from first four patients released December 13, 2016.
Resolaris
Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B

Latest News

  1. Atyr Pharma Stock Spikes 33% on FDA Updates
  2. FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
  3. ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure
  4. Roberts recuses from patent case after discovering conflict
  5. Roberts recuses from patent case after discovering conflict
  6. Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares
  7. Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers?
  8. aTyr Pharma downgraded by JP Morgan
  9. aTyr Pharma Drops on Clinical Update
  10. ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events
  11. aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris™ in Exploratory Trials
  12. aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference
  13. aTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
  14. ATYR PHARMA INC Financials
  15. aTyr Pharma Enters into $20 Million Credit Facility
  16. ATYR PHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive
  17. aTyr Pharma Enters into $20 Million Credit Facility
  18. aTyr Pharma (LIFE) Looks Good: Stock Adds 5.9% in Session
  19. aTyr Pharma Announces Third Quarter 2016 Operating Results
  20. ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits